Immunomedics has reported a 30% objective response rate after treating ten evaluable patients with inoperable advanced pancreatic cancer with the company's new targeted radiation therapy in combination with gemcitabine.
The interim results from the ongoing Phase II dose-escalation study were presented at the 2009 Annual Meeting of American Society of Clinical Oncology.
Immunomedics president and CEO Cynthia Sullivan said that the test data corroborated the notion that targeted radiation therapy was well suited for solid cancers.
"In light of the fact that there aren't many viable treatment options for patients with advanced pancreatic cancer, we believe clivatuzumab tetraxetan labelled with yttrium-90 is in a good position to become the first radioimmunotherapeutic agent for pancreatic cancer therapy," said Sullivan.
"We currently intend to develop it through commercialisation on our own."